Options

With the bull market now more than six years old, and with equity valuations being high, at least some of the cautious investors are starting to worry that the market could be ready for a big tumble.
Jon C. Ogg
What investors need to know is that analysts are cooling on their view of a potential Altera-Intel deal.
Jon C. Ogg
With Alcoa on the tape with numbers on Monday, and two big banks out Wednesday, the avalanche of fourth-quarter earnings will really hit the market next week in full force.
Lee Jackson
Source: ThinkstockThe end of July turned out to be ugly for equity investors, and August started off on the wrong foot as well. On the July 31 drop of 317 on the DJIA, all 30 of the Dow components...
Jon C. Ogg
Source: ThinkstockIn a report out this week, the Goldman Sachs options research team listed its top 25 tactical trades for earning season. While the report includes many names, the trick is to...
Jon C. Ogg
Source: courtesy of Radio ShackRadioShack Corp. (NYSE: RSH) is in serious trouble financially. Or is it? We have recently seen one of the credit ratings agencies warn of a potential restructuring...
Jon C. Ogg
Source: ThinkstockIf you have followed Warren Buffett and Berkshire Hathaway Inc. (NYSE: BRK-A) for very long, you know that Mr. Buffett loves to make acquisitions. He particularly likes the...
Jon C. Ogg
Source: ThinkstockFacebook, Inc. (NASDAQ: FB) is set to report earnings on Wednesday after the close. It turns out that some large investor must be worried about the stock dropping beyond a certain...
Jon C. Ogg
MannKind has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market for years, and that dream now seems to be within its grasp.
Jon C. Ogg
Yahoo! may be down about 7% after its earnings signaled what is still a lack of serious growth in its turnaround strategy. What is interesting is that the options trading community is keeping a more...
Jon C. Ogg
Ariad Pharmaceuticals could be joining the ranks of the next big biotech acquisitions. The company fits the bill of many biotech acquirers because its market cap is just over $1 billion and its...
Jon C. Ogg
Source: ThinkstockMannKind Corp. (NASDAQ: MNKD) is a stock that has been on a wild ride for many years. The company’s inhalable insulin has been held up from being approved for years as well. That...
Jon C. Ogg
Source: TwitterTwitter Inc. (NYSE: TWTR) became a legal short sell this week. That should include the caveat of whether your brokerage firm could even find shares to borrow. One trader told us he was...
Jon C. Ogg
Source: twitter.com/jimmykimmelThis week will mark two key events for the post-IPO trading of Twitter Inc. (NYSE: TWTR). The first issue is that traders and investors will begin to be able to legally...
Jon C. Ogg
Source: courtesy of Tesla MotorsTesla Motors Inc. (NASDAQ: TSLA) is set to report earnings on Tuesday and all eyes are going to be on the electric car maker’s results. Expectations will be very...
Jon C. Ogg